CytomX Therapeutics (CTMX) Set to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $10.38 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $1.42 million during the quarter, compared to analyst estimates of $12.39 million. CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%. On average, analysts expect CytomX Therapeutics to post ($0.40) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

CytomX Therapeutics Price Performance

CTMX stock opened at $2.36 on Thursday. The company has a market capitalization of $514.24 million, a P/E ratio of -4.72 and a beta of 2.21. CytomX Therapeutics has a 12 month low of $2.16 and a 12 month high of $8.21. The firm’s fifty day simple moving average is $2.87 and its 200-day simple moving average is $3.89.

Analysts Set New Price Targets

A number of equities analysts have weighed in on CTMX shares. JPMorgan Chase & Co. reduced their price objective on CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. Zacks Research downgraded CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Guggenheim dropped their target price on CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Wall Street Zen cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a research report on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.90.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.